HIGHLIGHTS
- who: Takeshi Aoyama from the DepartmentShowa University Japan have published the Article: Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma, in the Journal: Scientific Reports Scientific Reports
- what: Twelve patients were excluded for the following reasons: disease progressed before blood sampling (n=5); blood sample not collected (n=6); and agreed to withdraw (n=1). The primary reason for discontinuation was hepatotoxicity (5/14, 35.7%), and nausea or vomiting (1/14, 7.1%). This study investigated the pazopanib plasma trough concentrations in Japanese patients with . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.